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ABSTRACT 
Effects of Chronic Electronic Cigarette Use on Glucose Metabolism 
Hannah Hoskinson 
Traditional cigarette usage has been linked to a number of nefarious metabolic effects, 
including insulin resistance; however, the effects of electronic cigarettes (E-cigs) are not 
currently known. Advertised as a safe alternative for traditional tobacco cigarettes, E-cigs still 
contain some of the same harmful chemicals as tobacco cigarettes. Through this study, we hope 
to gain perspective on whether e-cigs play into the development of altered glucose homeostasis. 
C57BL/6 mice were divided between E-cig (n=15) and control (n=15) groups and exposed to 
either cappuccino flavored E-cig vapor or filtered air for 4 h/d, 5 d/wk for 8 months. Fasting 
blood glucose (FBG) and glucose tolerance were observed after 6 months of exposure. Glucose 
was administered either orally or IP at 2g glucose/kg body mass. Following an overnight fast, an 
oral glucose tolerance test (OGTT) was performed prior to E-cig exposure; on a separate day 
another OGT was performed immediately after a 4-hour exposure period. In addition, an 
intraperitoneal glucose tolerance test (IPGTT) was performed immediately after a 4-hour 
exposure period in a subset of mice (N=4).  
At the conclusion of 8 months of exposure, pancreas tissue was harvested and assessed in 
a subset of mice (n=6). Total body mass was similar between E-cig and air exposed groups at six 
months (E-cig: 28.7 ±1.1g vs Control: 28.8 ±1.45g) and eight months (E-cig: 29.5±1.62g vs 
Control: 28.9±1.06g). FBG prior to E-cig exposure tended to be higher in E-cig vs control mice 
(p=.13), while glucose following exposure were increased in the E-cig group (143.8±6mg/dL vs. 
118.8±8mg/dL, p=0.05). During the IPGTT, E-cig animals presented with a higher peak blood 
glucose (225±7mg/dL vs. 180±15mg/dL, p=0.03), as well as a higher total area under the curve 
(AUC) than controls (18228 ± 742 vs 15069 ± 667 respectively, p=0.02). E-cig animals did not 
have a different β-cell density, insulin positive area, or number of SIRT1(+) nuclei. However, 
SIRT1 density (determined by number of SIRT1(+) nuclei/islet area) was lower in E-cig mice 
versus control  (E-cig: 2.8E-4 ± 5.0E-5 nuclei/µm vs Controls: 4.4E-4 ± 5.0E-5 nuclei/µm, 
p=0.05). Total SIRT1 (E-cig: 1449 ± 301ng vs Control: 1297 ± 251ng) and UCP2 (E-cig: 0.08 ± 
0.009 vs. Control: 0.10 ± 0.01, AU) protein in the pancreas was not different between groups. In 
conclusion, chronic exposure to E-cig vapor resulted in modestly higher resting and stimulated 
blood glucose. Although total pancreatic SIRT1 protein levels were not affected, the density of 
SIRT1 positive β-cells was reduced in E-cig animals. Future research needs to determine if other 
pancreatic proteins and mechanisms are negatively affected because of E-cig exposure. 
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ABBREVIATIONS  
E-cig Electronic cigarette 
T2DM Type 2 Diabetes Mellitus  
UCP Uncoupling protein 
GLUT4 Glucose transporter 4 
PI3K Phosphoinositide 3-kinase 
DHEA Dehydroepiandrosterone  
ACTH Adrenocorticotropic hormone 
HbA1C Hemoglobin a1C 
HDL High density lipoprotein 
VLDL Very-low density lipoprotein 
HOMA-IR Homeostatic model assessment of insulin resistance 
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CHAPTER 1: INTRODUCTION 
	  
Approximately 17% of all Americans smoke cigarettes (CDC), and many of them are 
aware of the associated negative health effects. In their search for cessation help, one in five 
smokers turn to electronic cigarettes (E-cigs) (1). Smoking is often linked with metabolic 
syndrome, a state characterized by increased plasma lipids, obesity, hypertension, and insulin 
resistance; this pathology currently affects almost one-fourth of the world’s population (2). One 
of the hallmark components of metabolic syndrome is impaired glucose tolerance as a result of 
impaired insulin secretion and/or impaired peripheral insulin sensitivity. 
Traditional tobacco use through cigarettes is known to increase the risk of developing 
insulin resistance (3, 4, 5, 6) and type II diabetes (T2DM) (7, 8, 9, 10, 11, 12), mostly due to 
nicotine’s effects on the brain and organ systems.  The two major hallmarks of these pathologies 
are an aberrant insulin production by the pancreas and an altered action of insulin in peripheral 
tissues (29, 31). In a healthy individual, a rise in blood glucose activates the islets of Langerhans 
within the β-cells of the pancreas to release insulin, a peptide hormone responsible for regulating 
the metabolism of circulating fats and carbohydrates (29). Some studies have linked nicotine 
directly to the dysfunction and destruction of pancreatic β-cells (2, 13). It has also been shown 
that smoking and its associated lifestyle causes a reduction in β-cell function (10, 14) as well as a 
greater demand on the β-cells to maintain blood glucose (9), due to increased stimulation of 
gluconeogenic pathways such as cathecholamines. When blood glucose maintenance places 
increased strain on the β-cells, this can overwhelm the cells and cause them to atrophy, a T2DM 
phenotype (9). A reduction in size of the β-cells is often followed by a reduction in overall 
function, leading to mishandling of carbohydrates and lipids causing hyperglycemia (15). 
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Nicotine may also indirectly affect blood glucose levels via the alpha cells of the 
pancreas, which govern the secretion of glucagon. When nicotine enters the body, it stimulates 
nicotinic acetylcholine receptors in the brain and causes the release of catecholamines from the 
adrenal medulla (16, 17). The release of catecholamines is known to inhibit the release of insulin 
and to possibly stimulate the release of glucagon from the alpha cells of the pancreas (18). When 
alpha cells are stimulated to release glucagon into a normoglycemic individual, blood glucose 
concentrations can rise above what is normal and safe, thus creating a hyperglycemic state (19). 
Uncoupling proteins (UCPs) have recently been identified as possible mediators in the 
development of obesity and obesity-related disease states (20). UCPs are located in the 
mitochondrial membrane of cells and are responsible for dissipating the proton gradient created 
by the process of generating ATP, thus uncoupling oxidative phosphorylation from the synthesis 
of energetic molecules (21). Though several different forms exist with specific targets and 
mechanisms, UCP2 has been identified in the pancreas and appears to play a role in insulin 
secretion (21). 
When UCP2 uncouples the breakdown of glucose and the production of energy, it causes 
the available ATP/ADP ratio to decrease (18).  In the β-cells, the presence of ATP induces 
insulin secretion by activating ATP-sensitive K+ channels. The K+ channels control the 
membrane potential of the cell, and when the channels close the membrane begins to depolarize 
which facilitates the influx of calcium, and ultimately increases the rate at which insulin is 
expelled via exocytosis (18). Since UCP2 decreases the amount of ATP present in the cell and 
that energy is then lost as heat, it could also indirectly decrease the amount of insulin released by 
the pancreas in response to a rise in plasma glucose (22). 
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One of the proposed key regulators of pancreatic UCP2 is sirtuin 1 (SIRT1) (23), a 
NAD+ dependent protein deacetylase that exists in both the nucleus and cytoplasm of β-cells 
(24). In the nucleus, SIRT1 deacetylates histone complexes to suppress transcription of certain 
genes. SIRT1 has also been proposed as one of the major players in whole-body insulin 
sensitivity, based on its dependence upon the NAD+/NADH or energy ratio within the cell (25). 
The presence of SIRT1 has been related to normal function and increased longevity of the β-cells 
(21), and increasing functional SIRT1 will decrease UCP2 (23) and inhibit β-cell apoptosis (26), 
thus preserving the cells’ ability to release appropriate amounts of insulin in response to stimuli. 
If this mechanism is affected by damage incurred by nicotine either directly or indirectly through 
nicotine’s role in hyperglycemia, it could further exacerbate the condition of increased blood 
glucose caused by nicotine. 
SIRT1 has been found to function two ways in the pancreas: through UCP2 (21, 23, 26), 
and through the Forkhead box O1 (FoxO1) pathway (27, 28). FoxO1 is a transcription factor 
thought to be essential for proper pancreatic differentiation, maturity, and overall function (27). 
When FoxO1 is inactivated, it allows insulin to have a more profound effect on suppressing 
glucose release from the liver (28), thus allowing insulin to reduce blood glucose levels to safe 
values before allowing hepatic glucose stores to compensate for the fall in glucose. SIRT1 is 
thought to inactivate FoxO1, which limits the amount of its transcription. FoxO1 plays a 
dynamic role in proliferation of pancreatic tissue and specifically in the formation of β-cells (98). 
The primary objective of this study is to examine the effect of nicotine in combination 
with the other chemicals present in E-cig vapor on glucose metabolism and pancreatic health. 
The central hypothesis is that prolonged exposure to E-cig vapor will reduce β-cell number and 
pancreatic islet area and reduce SIRT1 and its dependent processes.  Our rationale for conducting 
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this study rests upon, in part, preliminary data demonstrating that animals exposed to 6-months 
of E-cig smoke had a significantly higher glucose profile compared with controls following an IP 
glucose challenge. This study will examine if this is related to altered pancreatic morphology and 
potential function. The proposed study looks to identify the consequences of E-cig exposure on 
glucose metabolism, and therefore determine the potential long-term effects of E-cigs on health. 
It is critical to provide more research on this topic in order to inform the general public on the 
possible negative effects these devices may have. The aim of this study is to:  
Specific	  Aim	  1: Examine the pancreatic β-cell number and islet area in mouse pancreas 
after being exposed to eight months of E-cig smoke. 
The working hypothesis is that prolonged exposure to E-cig smoke will cause a reduction 
in both β-cell density and islet area compared with controls. 
Specific	  Aim	  2: Determine the effects of an eight-month E-cig exposure on pancreatic 
SIRT1 and its related proteins. 
The working hypothesis is that prolonged exposure to E-cig smoke will cause a reduced 
number of SIRT1 positive β-cells, a reduced pancreatic SIRT1 protein content, and an 
increase in pancreatic UCP2 protein levels. 
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CHAPTER 2: BACKGROUND AND SIGNIFICANCE 
2.1	  Glucose	  Regulation	  and	  Metabolism	  
	  
        In order to function properly, the body requires glucose levels to be within a narrow 
range. This is maintained by a multitude of factors and mechanisms, governed largely by 
hormones (103). Under low glucose conditions, the pancreas is stimulated to release glucagon 
and when blood glucose is high, the pancreas is stimulated to release insulin (103). Glucagon is a 
peptide hormone and is produced by the α-cells of the pancreas and promotes gluconeogenesis 
and glycogenolysis to raise or maintain blood glucose (104). Insulin is also a peptide hormone 
produced by the β-cells within the Islet of Langerhans of the endocrine pancreas (104). It is 
responsible for facilitating the degradation of carbohydrates into energy sources (104).  
        When a meal is ingested, glucose is taken up into cells and broken down to derive ATP 
via glycolysis, thus increasing the intracellular ATP/ADP ratio (105). This increase in 
intracellular ATP causes ATP-sensitive potassium channels to close, which depolarizes the 
membrane of the cell and therefore opens voltage-gated calcium channels (18). The opening of 
these channels causes an influx of Ca2+ ions and stimulates the translocation of insulin vesicles 
to the cell membrane, thus allowing the release of insulin into the extracellular fluid of the 
pancreas where it is taken up into the bloodstream and delivered to extrapancreatic tissues (18). 
        Insulin has a variety of targets (the liver, brain, muscle, and adipose tissue to name a few) 
(46). Glucose transporter 4 (GLUT4) is insulin stimulated and is responsible for glucose entry 
into muscle cells. When insulin is present, phosphatidylinositol 3-kinase (PI3K) is recruited to 
the plasma membrane (53), which subsequently recruits Akt to the plasma membrane as well. 
The presence of this phosphorylated Akt at the membrane has been shown to facilitate the 
translocation of the glucose transporters (54, 55), as well as upregulating the efficacy of 
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hexokinase (the first enzyme in glycolysis) (56, 57). Akt regulates not only the entry of glucose 
into the cells via glucose transporters but also the rate at which the glucose can be used by the 
cell to create energy (58). 
Insulin also has profound effects on adipose tissue, promoting lipid synthesis and 
reducing the rate of lipid catabolism (46). In most tissues, insulin’s efficacy depends on the 
presence of receptors. Consisting of two α- and two β-subunits, insulin binds to the α-subunit to 
activate the intracellular tyrosine kinase (46). The β-subunits autophosphorylate each other and 
are responsible for inducing the event cascade intracellularly. Once the receptor is activated, 
recruitment of receptor substrates begins. These insulin receptor substrates (IRS) are a diverse 
family of proteins responsible for overseeing the cascade of signaling events in response to 
insulin release (29, 30).  
Some glucose transporters, such as GLUT2, do not rely on insulin and are the primary 
glucose transportation device of pancreatic β-cells in mice and function similarly in humans (64). 
After developing persistent hyperglycemia, mouse GLUT2 has been shown to decrease 
substantially (65), limiting the ability of the pancreas to take up and therefore sense changes in 
concentration of glucose. 
2.2	  Metabolic	  Syndrome	  
 Metabolic syndrome is an umbrella term for a cluster of risk factors predicting 
cardiovascular disease (CVD) and type II diabetes mellitus (T2DM), which include 
hypertriglyceridemia, hypercholesterolemia, hypertension, excessive central adiposity, and 
insulin resistance. In terms of glucose regulation, dyslipidemia and insulin insensitivity create the 
most poignant issues (31). Insulin resistance is a condition in which a normal concentration of 
insulin does not produce a matched effect in insulin action at the periphery (31). This blunted 
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peripheral response stimulates the β-cells to release more insulin, causing hyperinsulinemia to 
overcome the sustained hyperglycemia. When this state is prolonged, both the target tissues and 
the β-cells become overwhelmed, causing the tissue’s receptor density and function to decrease 
(32) and the β-cells to become damaged (33, 34). T2DM occurs in those organisms whose β-cells 
are unable to adequately compensate, resulting in sustained hyperglycemia (35). 
 Prolonged states of hyperglycemia such as those seen with the T2DM phenotype have 
been associated with an initial increase in mass of the β-cells as they attempt to compensate and 
continue regulating glucose and insulin levels (66). The β-cell mass is maintained or increased 
(67, 68) by islet neogenesis and β-cell hypertrophy and/or replication (66).  Issues arise when the 
pancreas can no longer regulate glucose levels within a normal range and are marked by a 
reduced ability to release insulin based on glucose levels, or glucose-stimulated insulin secretion 
(GSIS) (66, 73). In addition to increases in β-cell mass, the β-cells can compensate by increasing 
in function (69, 70, 71). Increased circulating glucose results in an upregulation of glycolysis, 
which will alter the ATP/ADP ratio, causing upregulation of the K+ ATP-dependent pathway 
responsible for releasing insulin granules (72).  
Dyslipidemia is characterized as increased low-density lipoprotein (LDL) (plasma 
cholesterol and/or triglycerides) and decreased high-density lipoprotein (HDL), and can be 
caused by genetic or environmental factors (36). Dyslipidemia often stems from excessive 
caloric intake from a diet rich in fats (40), but in conjunction with insulin resistance, the 
condition is worsened. Hepatic  very low-density lipoprotein (VLDL) synthesis from hepatic 
stores is increased, which directly exacerbates the hyperlipidemic state (37). HDL and insulin 
have also been shown to have an inverse relationship (37, 38), so the hyperinsulinemic individual 
will have lower circulating HDL due to an uncompensated rate of degradation of apoA-I/HDL 
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(39). Abnormal lipid profiles have been linked with numerous metabolic consequences, many of 
which decrease overall health and quality of life. 
2.3	  E-­‐cigs	  	  
 E-cigs, devices offer an alternative smoking experience by delivering nicotine, 
flavorings, and other additives. Their appeal is not only to those who smoke (1 in 5 smokers will 
turn to E-cigs as a smoking cessation tool) (1), but also as a gateway into smoking (41). 
Regardless of their target consumer, E-cig companies advertise their products as “safe” and 
containing “just vapor”, but without strict FDA guidelines, ingredients are not regulated. E-liquid 
is generally composed of three basic components: a humectant (propylene glycol and/or 
vegetable glycerin), nicotine in varying concentrations, and flavorings comprised of different 
additives (78). These liquid ingredients are then passed through a heating element, which are 
vaporized and delivered to the smoker.  
 Propylene glycol (PG) is a chemical used widely in cosmetics, antifreeze, detergents, 
paints, and as an FDA-approved additive in food (42). Acute exposure to PG is a known irritant 
to the human airway (43, 44), facilitates infiltration of pro-inflammatory markers such as IL-6 
(44), and is a known carcinogen (45). The other base chemical widely used in E-liquid is 
vegetable glycerin (VG), which also acts as a humectant, solvent, and sweetener. VG is non-
toxic and used in foods and pharmaceuticals. Glycerin, also called glycerol, can enter either 
glycolysis or gluconeogenesis via glycerol kinase where it can be used to synthesize energetic 
material or contribute to glucose stores (94).  
 PG can be oxidized at relatively low temperatures (127-227°C) to yield formaldehyde, 
acetaldehyde, and carbon dioxide and can form acetone via a dehydration reaction (74). Glycerol 
dehydration results in formation of acrolein (75), an electrophilic compound with a very high 
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toxicity. When PG and glycerol reach high enough temperatures (as they often do within the E-
cigs, due either to intentional heating to get more smoke or unintentionally through accidental 
overheating), they degrade to form these dangerous carbonyl compounds (76).  
Nicotine is the first of the optional additives to E-liquid. Concentrations vary between 0-
>50mg/mL, which is roughly equivalent to the nicotine content available in tobacco cigarettes 
(114). It has been seen that when nicotine levels decrease, smokers often compensate by smoking 
more often, essentially reaching the same nicotine levels (77). While this tendency is not only 
counterproductive to the concept of reducing nicotine intake, it also may inadvertently cause 
overheating of the E-cig device and result in the greater creation of harmful carbonyl compounds 
delivered to the user.  
Flavorings are the final main component available in many E-liquids. Hundreds of brands 
and thousands of flavors currently exist (78), with many flavors seemingly marketed toward 
adolescents or those who may never otherwise used a nicotine delivery product before (79). 
Many of the additives used to make the flavors are the same as used by the food industry to 
enhance the flavors in food (79), but although these compounds have been deemed safe for 
ingestion, little to no evidence exists supporting their safety for inhalation. In fact, chronic 
exposure to aerosolized diacetyl, or 2,3-butanedione (used to give foods a butter flavor), has 
been proven to cause Bronchiolitis obliterans, or “popcorn lung” (79, 80). Evaluation of E-
liquids has shown that diacetyl is present in numerous flavors, resulting in exposure over the 
limits set forth by OSHA (81, 82). In addition to being harmful to the pulmonary system, these 
chemical additives have also been shown to cause the secretion of pro-inflammatory cytokines 
and increase oxidative stress in lung tissue (83).  
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2.4	  Smoking	  and	  the	  Pancreas	  
 Smoking has been linked with insulin resistance (3, 4, 5, 6) and altered lipid profiles (60), 
as well as the development of T2DM (7, 8, 9, 10, 11, 12). The main and addictive ingredient in 
tobacco cigarettes is nicotine, which is also present in varying concentrations in E-cig liquids. 
Nicotine is rapidly absorbed in the alveoli of the lung and enters the bloodstream. When it 
reaches the brain, it binds to nicotinic cholinergic receptors (62) and begins a marked response in 
the hypothalamic-pituitary-adrenal (HPA) axis (16). In a dose dependent manner, the absorption 
of nicotine sparks the release of glucocorticoids and catecholamines, specifically 
adrenocorticotropic hormone (ACTH), cortisol, epinephrine, and dehydroepiandrosterone 
(DHEA) (16). The presence of glucocorticoids has been shown to directly inhibit the release of 
insulin (84) from β-cells while catecholamines stimulate the release of glucagon to elevate blood 
glucose (85) partially via the α-cells. Both of these effects exacerbate the other, creating and 
propagating the hyperglycemic state. Both heavy and light smoking have been associated with 
changes in carbohydrate metabolism. HbA1c, which refers to glycated hemoglobin, has been 
long established as an accepted method of estimating average blood glucose over a period of 
weeks to months. Elevated levels have been seen in smokers (86), as well as a very high 
prevalence of impaired fasting glucose  (86). 
The literature on nicotine’s effect on the pancreas is not all in agreement. Studies in rats 
injected with nicotine have found no differences in blood glucose, but did find that plasma 
insulin concentrations were significantly decreased as well as the homeostatic model assessment 
of insulin resistance (HOMA IR), which relates fasting glucose, insulin, and C-peptide 
concentrations (87). This supports the notion that nicotine increases insulin sensitivity in an acute 
manner. Long-term suppression of these cells may have a different effect. Studies have also 
shown that the insulin requirement for smokers is higher to maintain the same glucose reading as 
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non-smokers (9) in exogenous insulin-dependent diabetic patients. Examination of post-smoking 
oral glucose tolerance tests in rats have also shown impairments, even when compared to a non-
smoking glucose tolerance test of the same individual (88). 
Very few studies have examined the effect of E-cig vapor on glucose homeostasis, but 
there exists some evidence that E-cig vapor both with and without nicotine increases glycemia 
(89). The same study also recorded a significantly decreased hepatic glycogen breakdown in both 
nicotine-containing and non-nicotine containing E-cig vapors (89), leading to the postulation that 
these animals are calling upon glycogen stores to maintain an elevated blood glucose level. 
In addition to acute effects on blood concentrations of hormones, smoking and nicotine 
have been shown to have negative effects on the pancreas itself. There is some evidence that the 
β-cells themselves have nicotine receptors (13). Extracted β-cells from rat and human pancreas 
were exposed to varying concentrations of nicotine and their ability to release insulin decreased 
(13). Morphological differences have been seen as well, including reduced β-cell mass (90), 
increased β-cell apoptosis (90), and lesions and significant markers of inflammation (91) in 
pancreas exposed to chronic nicotine. β-cell function was also found to be decreased following 
nicotine exposure in human subjects via the HOMA β-cell function assessment (formula for 
deriving β-cell functionality from insulin and glucose levels) (92). 
2.5	  SIRT1	  
 One of the many regulating factors of physiological systems (and the pancreas 
specifically) is silent mating type information regulation 2 homolog, or SIRT1. The human SIRT 
proteins are orthologs to the family of yeast sirtuins and function to deacetylate proteins (NAD-
dependent) thereby increasing longevity of the genetic material via gene silencing (23, 47). The 
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SIRT family is thought to work through two basic mechanisms, UCP2 (23) and universal FoxO1 
(95). 
 Since UCP2 uncouples oxidative phosphorylation from the synthesis of energetic 
molecules, it causes the available ATP/ADP ratio to decrease (18). Pancreatic β-cells rely almost 
exclusively on this ratio to induce insulin secretion via ATP-sensitive K+ channels. Increased 
expression of UCP2 indirectly decreases the amount of insulin released in response to a rise in 
plasma glucose (22). It has been postulated that SIRT1 decreases UCP2 presence by binding 
directly to the UCP2 promoter in order to silence it (23), so when SIRT1 is present in acceptable 
levels it allows energy coupling to proceed as normal. Furthermore, reduction in UCP2 restores 
normal insulin secretion (23). When SIRT1 expression becomes impaired or decreased, UCP2 
expression is allowed to increase, thus uncoupling oxidation from phosphorylation of ADP and 
disturbing the energetic state of the cell - and by extension, the insulin response. Mice with 
insulin resistance exhibited decreased SIRT1 protein levels in muscle compared to unimpaired 
controls (50) and decreased blood insulin levels (23). It has also been shown that increasing 
expression of SIRT1 can improve insulin sensitivity (50).  
The other main component of the SIRT1 is the FoxO1 pathway. FoxO1 is inhibited by 
insulin via the Akt pathway (96) and changes in FoxO1 levels have been shown to have negative 
effects on insulin sensitivity (97). In the pancreas, FoxO1 is produced exclusively within the β-
cells, and is thought to play a vital role in cell proliferation and formation of β-cells during 
growth as well as stress resistance (98). During formation of the pancreas, FoxO1 is widely 
produced in the epithelium of the pancreas (100). Mouse embryos lacking FoxO1 do not develop 
fully mature vasculature, so pancreas-specific FoxO1 deficiency in early development has not 
been able to be studied (101); however, FoxO1 has been identified as a negative regulator of 
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differentiation in human fetal pancreas due to its inhibitory effects on crucial transcription 
factors such as NGN3 and NKX6-1 (98). During bouts of oxidative stress, FoxO1 is translocated 
into the nucleus of the β-cell, where it acts to restrict growth or further proliferation in order to 
prevent further oxidative damage to the cell (99). Global overexpression of FoxO1 leads to 
impaired glucose, insulin, and triglyceride levels when fasted but reduced glucose, insulin, and 
triglyceride levels when fed (52).   
2.6	  Summary	  of	  Background	  &	  Significance	  
 With prevalence of E-cig use on the rise, it is important to better understand the impacts 
it may have on overall health. Exposure to nicotine may result in any number of negative effects 
may occur not only to airways and blood vessels, but also to the body’s ability to properly 
regulate glucose. In addition to nicotine, flavoring compounds also pose a threat to glucose 
homeostasis and could exacerbate or even induce hyperglycemia and dyslipidemia. These 
flavorings are neither listed nor considered a concern to the consumer when the constituents of 
their vaporized states are largely unknown. Dysfunction in glucose handling has become a 
national epidemic, and there exists a need to understand more fully what these devices are 
releasing and their metabolic consequences. A base body of knowledge must exist before these 
products can be readily advertised as a safe alternative, a body that is currently absent. 
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CHAPTER 3: STUDY DESIGN & METHODS 
Study	  Design	  
Thirty female C57BL/6 mice aged 10 weeks were purchased from Jackson Laboratory 
(stock #000664, Bar Harbor, ME) and randomly assigned into E-cig vapor (cappuccino-flavored, 
18mg/ml nicotine) (N=15) or filtered-air groups  (N=15). After one week of adaptation to the 
new vivarium, baseline testing occurred and at 13-14 weeks of age, exposures began and lasted 
for 8 months. This protocol translates to smoking exposure from approximately 11-35 years of 
age assuming a total life span of 2 and 78 years for mice and men, respectively. Mice were group 
housed (4-5 animals, within exposure groups) in a temperature controlled (22 ± 4°C, relative 
humidity 39 ± 6%) and pathogen free vivarium room with maintained 12hr light/dark cycle. 
Animals had ad libitum access to standard chow (18% fat, 24% protein, 58% carbohydrates) and 
tap water except when otherwise noted. All procedures were approved by the WVU Institutional 
Animal Care and Use committee. 
Exposure	  
Mice were exposed using identical 15.1 L whole body exposure chambers. E-cig vapor 
were gradually introduced during the first 8 weeks, beginning at one hour a day up to four hours 
a day. After each hour exposure, a washout period of 30 minutes of fresh air occurred, allowing 
the chamber to clear and mice to recover. This paradigm continued for 5 days/week for a total of 
8 months. The E-cig device was a 3rd generation, tank-style, device purchased online (eGrip 
OLED, Joyetech, www.joyetech.com). The E-cig voltage was set to 4.8 V, and was activated 
every 99 seconds for a 5-second duration, resulting in ~38-39 puffs each hour. The device was 
controlled by a custom-made artificial hand with an automatic switch attached to a timer. Vapor 
was generated and delivered to the respective chambers with rodent ventilators (Harvard 
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Apparatus, Natick, MA) using 55 ml tidal puff volume. Control mice received filtered (Carbon 
Cap 150, Whatman) from a central compressed air line.  
Blood	  Glucose	  Measurements	  
 After six months of exposure, a series of glucose tolerance tests were administered to a 
subset of mice. For test one, an oral glucose tolerance test (OGTT) was administered to animals 
following an 8 hour fast. Each animal was placed into its own cage and a fasting glucose reading 
was taken via nick in the tail vein using the Bayer Contour ® glucometer and strips. A glucose 
bolus (2g/kg body mass) was then administered orally (via gelatin pellet containing a calculated 
amount of glucose). Mice were trained for two weeks to eat the glucose pellet and any mouse not 
completing the entire pellet in less than two minutes was excluded from the test. Blood glucose 
measurements were made at 15, 30, 60, 90, and 120 minutes post-ingestion. For test two, another 
OGTT was administered following an 8-hour fast. During this fast, mice were exposed to their 
normal 4-hour bout of vapor exposure. Following exposure, a fasting blood glucose reading was 
taken. A glucose bolus (2g/kg body mass) was then administered orally via gelatin pellet 
containing a calculated amount of glucose. Any mouse not completing the entire pellet in less 
than two minutes was excluded from the test. Subsequent glucose measurements were made at 
15, 30, 60, 90, and 120 minutes post-ingestion. Because we noticed a trend for resting blood 
glucose to be higher in E-cig but had some difficulty getting all mice to reliably complete the 
glucose pellet after exposure, we chose to do a third glucose test. The third glucose test was an 
intraperitoneal glucose tolerance test (IPGTT) performed on a subset of mice post-vapor 
exposure. During this test, animals were fasted for eight hours and during the eight hours, the 
usual 4-hour bout of vapor exposure was carried out. Once the fast and smoke exposures were 
completed, each animal was individually housed and a fasting blood glucose reading was taken. 
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Each mouse then received a bolus of glucose (2g glucose/kg body mass) via IP injection. 
Subsequent glucose measurements were made at 15, 30, 60, 90, and 120 minutes post-injection. 
Immunohistochemistry	  
 Following 8-months of exposure, mice were euthanized and their pancreas tissue 
surgically removed. Fresh pancreas samples were mounted to cork and flash frozen using tissue 
embedding medium (OCT, Tissue Tek) and isopentane, then stored at -80°C until used for IHC. 
Samples were sliced into 10µm thick sections using the Leica CM3050S cryostat at -20°C. 
Sections were placed on glass slides and fixed in 4% paraformaldehyde solution for 20 minutes. 
0.2% Triton X-100 was used to permeabilize the samples for 10 minutes, then the slides were 
blocked for 1 hour using goat serum. The primary antibodies used were Insulin (C27C9) Rabbit 
mAb #3014 (Cell Signaling Technology) and SIRT1 (Cell Signaling Technology) and allowed to 
incubate overnight. Secondary antibodies were Alexafluor 555 IgG anti-rabbit and Alexafluor 
488 IgG anti-mouse (ThermoFisher and Fisher Scientific, respectively) and were incubated for 
45 minutes. Slides were imaged using SPOT5.2 Advanced program. Images were analyzed using 
ImageJ.  
Islet	  morphology	  and	  β-­‐cells	  counting	  
15 islets islets from each animal (N=6 animals for each group) were analyzed and β-cells 
counted individually from each islet using Image J. Image J was also used to determine islet area 
in µm. Individual nuclei were stained with DAPI and counted within the insulin positive area to 
determine β-cell number. Individual nuclei that expressed SIRT1 fluorescence were also counted 
and then normalized to islet area. 
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Western	  Blotting	  
Pancreas was homogenized in Tris-buffered saline containing 50mM tris/HCl, 150mM 
NaCl, 0.5% Triton X-100, Protease Inhibitor Tablet, and H2O using the BeadMill system. 
Samples were then incubated for 40 minutes at 4°C with agitation, and centrifuged (16,100g, 20 
min, at 4°C). Samples were stored at − 80 °C. 
Total protein was measured by Bradford assay (#23236 Pierce Coomassie Plus Protein 
Assay Kit, Thermo Scientific, Rockford, IL) using bovine serum albumin standards.  
Protein samples were electrophoresed with a 4-12% Bis-Tris (Criterion XT Precast Gel 4-
12% Bis-Tris,Hercules CA) gel and blotted onto a 0.45um nitrocellulose membrane (Pierce 
nitrocellulose membrane, Thermo Scientific, Rockford, IL). After blocking with 5% fat-free 
milk, membranes were probed at 4°C for 24 hours by gentle rocking. Antibodies included: 
SIRT1 (Polyclonal rabbit IgG, Invitrogen: Rockford, IL, #PA5-17232), UCP2 (Polyclonal rabbit 
IgG, Invitrogen: Rockford, IL, #Pa5-36383), and FOXO1 (Monoclonal rabbit IgG, Invitrogen: 
Rockford, IL). 
Chemiluminescent detection (Pierce ECL, Thermo Scientific, Rockford, IL) was carried 
out to visualize proteins and digitally imaged (G∶BOX Gel imager, Syngene, Cambridge, UK) 
using Genesnap software (Ver. 7.01, Syngene, Cambridge, UK). β-tubulin was used as the 
housekeeping gene. Quantification of protein expression levels were carried out using NIH 
Image J Software (v1.62) and expressed as densitometric arbitrary units (AU). 
ELISA	  
 Whole pancreas SIRT1 was assessed via ELISA kit (Mouse SIRT1 ELISA Kit, Abcam®, 
#ab206983) according to the manufacturer instructions. Primary antibody incubation was 
performed for 3 hours and total protein content in each well was 350ug. 
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Statistical	  Analysis	  	  
 All data are represented as a mean ± SE, with a criterion of P < .05 for significance and 
were assessed using T-tests. r-ANOVA were used to analyze glucose tolerance curves. 
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CHAPTER 4: RESULTS 
Body	  Weights	  
 The body weights were similar throughout the entire study and the growth curves 
followed roughly the same shape (Figure 1A). They did not reach any statistical difference at the 
six-month time point (E:cig: 28.7 ±1.1g vs Control: 28.8 ±1.5g)  (Figure 1B) or the eight-month 
time point (E-cig: 29.5±1.6g vs Control: 28.9±1.1g) (Figure 1C).  
Glucose	  Testing	  
 Although trending somewhat higher, resting blood glucose was not different without 
exposure (E-cig: 141±10mg/dL vs Control: 123±6 mg/dL, p=0.137) (Figure 2A) or after a 
typical 4-hour exposure period (E-cig: 146±10 mg/dL vs Control: 142±10 mg/dL) (Figure 2B). 
Following the OGTT, glucose curves were also not different without (Figure 2C) or after 
exposure (Figure 2D). Fasting blood glucose after exposure at six months exposure was 
significantly higher when assessed prior to IPGTT in the same selected group of E-cig mice 
(144mg/dL) compared to control (119mg/dL)  (p=0.05) (Figure 3). During the IPGTT, E-cig 
mice demonstrated an impaired capacity to clear glucose and presented with a higher glucose 
curve (Figure 4A). Figure 4B shows E-cigs IPGTT curve normalized for their higher baseline, 
with significance at 15 and 60 minutes (P=0.05). Additionally, peak glucose (at 15min post IP 
injection) was significantly higher in E-cigs compared with control mice (225mg/dL vs 
180md/dL respectively, p<0.05) (Figure 4C).  Total glucose (area under the curve) was also 
significantly greater in E-cig versus control mice  (p<0.05, Figure 4D).  
β-­‐cell	  Number	  per	  Islet	  (β-­‐cell	  density)	  
 The average number of β cells per islet was examined by counting individual DAPI 
stained β-cells within the insulin stained positive area and used to calculate β-cell density. Mean 
β-cell number was not significantly different between groups (E-cig: 66±10 vs Control: 68±10) 
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(Figure 5A). There was not a difference found between E-cig and control groups for β-cell 
density (E-cig: 2.1E-03 ± 2.0E-04 vs Contol: 1.9E-03 ± 6.0E-04) (Figure 5B). 
Islet	  Area	  
 Islet area was determined by measuring insulin positive morphology, and also showed no 
difference between groups (E-cig: 62,200 ± 12,733µm2  vs Control:  44,366 ± 8,730µm2 ) (Figure 
6A). Representative images of insulin and DAPI staining are located in Figure 6B.  
Mean	  SIRT1(+)	  Nuclei	  	  
 Mean SIRT1-positive nuclei were determined by counting the nuclei within the insulin 
positive area that were positive for SIRT1. A representation of this is shown in Figure 7A. No 
difference was seen in SIRT1(+) nuclei (E-cig: 14.7 ± 2.7 vs Control: 16.4 ± 1.9, Figure 7B), but 
when SIRT1 density was assessed (SIRT1(+) nuclei per islet area), E-cigs had a significantly 
decreased SIRT1 density (E-cig: 2.8E-04 ± 5.0E-05 vs Control: 4.4E-04 ± 5.0E-05 , p=0.05) 
(Figure 7C). 
SIRT1	  Expression	  in	  Whole	  Pancreas	  
 SIRT1 expression in whole pancreas was assessed via ELISA kit (Abcam). No significant 
difference was seen between the two groups (E-cig: 1449 ± 301ng vs Control: 1297 ± 251ng) 
(Figure 8). 
UCP2	  in	  Whole	  Pancreas	  	  
UCP2 expression in whole pancreas was assessed via Western Blot. No significant 
difference was seen between the two groups (E-cig: 0.08 ± 0.009AU vs. Control: 0.10 ± 0.01AU) 
(p=0.179) (Figure 9).  
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CHAPTER 5: DISCUSSION 
	  
 The primary objective of this study was to determine if chronic exposure to E-cig vapor 
has a negative effect on overall glucose metabolism and pancreatic health in mice. The central 
hypothesis was that long-term exposure to E-cig vapor would result in reduced β-cell density, 
pancreatic islet area, and SIRT1 positive cells. We also hypothesized that this would lead to a 
reduced protein expression of SIRT1 and an increased amount of UCP2 in the pancreas. The 
primary findings in this thesis were that 8 months of E-cig exposure led to no significant changes 
in β cell density or islet area when compared with control mice. Furthermore, 8 months of E-cig 
exposure did not result in a significant differences in total SIRT1(+) β-cells, SIRT1 protein, or 
increase in UCP2 protein in pancreas tissue. It did, however, reduce the density of SIRT1(+) β-
cells within the islets of the pancreas.  
Exposure to nicotine through regular cigarettes has been linked with insulin resistance (3, 
4, 5, 6) and the development of T2DM (7, 8, 9, 10, 11, 12). We proposed that exposure to E-cigs 
would create a similar effect on blood glucose based on the presence of nicotine in the vapor. 
After 6 months of exposure, resting blood glucose was not different between groups although 
there was a trend for higher values in the E-cig mice. After an acute exposure, fasting blood 
glucose levels in the E-cig mice were significantly higher than control. Although it is difficult to 
make general conclusions from this single time point on blood glucose measurements, it does 
suggest that acute exposure to E-cigs produced an exaggerated glucose response. These data are 
similar to those presented in other studies looking at nicotine (84, 85, 86), but thus far only one 
other study has focused primarily on blood glucose as it pertains to E-cig exposures. This study 
also reported an impaired glucose response following E-cig exposure (89).  
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To determine if glucose handling was also altered following chronic exposure to E-cigs, a 
two-hour OGTT was performed. No differences were observed between groups. We followed 
this by administering an OGTT following a 4-hour acute exposure. Again no differences were 
observed between groups. It is worth noting that we had a difficult time getting mice to fully 
consume the glucose pellet following the E-cig exposure. Therefore, we performed an IPGTT on 
a subset of mice because this had been shown to be a more reliable method for determining 
glucose tolerance (23). Results revealed a significantly increased area under the curve for the 
subset of E-cig animals tested. The general shapes of the curves were the same, but because 
glucose values in E-cig mice began at a higher fasting glucose level, they spiked higher and 
remained more hyperglycemic throughout the test when compared to the control animals. This is 
consistent with the literature stating that exposure to nicotine altars the glucose response profile 
(88). Xu et al (88) focused on nicotine’s effect on insulin and found it to be in inhibitor of insulin 
release; however, no plasma insulin or HbA1c measurements were taken during our study, which 
limits the interpretation of our results.  An insulin tolerance test was performed, but unforeseen 
circumstances within the test caused an early termination and no results. Still notable, however, 
was during that aborted test, E-cig mice did have higher glucose levels following an IP glucose 
injection and did not experience the extreme hypoglycemia seen within the control group. Narges 
et al (108) found hyperglycemia was induced after exposure to E-liquid, even with liquid 
containing no nicotine. This supports our trend that even without the acute presence of nitocine, 
glucose metabolism is altered due to chronic E-liquid exposure. 
 Other studies have linked nicotine directly to the dysfunction and destruction of 
pancreatic β-cells (2, 13). Because of these results, the focus of this thesis was primarily on 
potential changes to the pancreas as a result of E-cig exposure, which could lead to reduced 
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insulin formation and secretion. Weir and Bonner-Weir (106) have described five stages of β-cell 
dysfunction as a result of obesity. Stage 1 is characterized by increased levels of plasma insulin, 
β-cell hypertrophy, and increased acute GSIS (106). Stage 2 is when truly normal glucose levels 
can no longer be maintained for any length of time and loss of acute GSIS (106). Stage 3 is 
unstable early decompensation (inability to properly regulate glucose and beginning stages of β-
cell dysfunction), and stage 4 is stable decompensation. Finally, stage 5 is severe 
decompensation as full-blown diabetes (usually only T1DM) (106).  
We hypothesized that an eight-month exposure to E-cig vapor would result in 
morphological differences in the pancreas. Decreases in both islet size and β-cell density within 
insulin-positive area were expected, however our results showed no difference in these variables 
between groups. These findings are not consistent with one report in the literature by El Golli et 
al, who found that chronic exposure to smoke caused decreases in islet size and β-cell density 
(90). Islet area appeared to be larger in the E-cig mice but lacked statistical significance based on 
a small sample size and high variability of measure. Based on the Weir and Bonner-Weir 
principle, it is likely these E-cig animals were still in Stage 3 of dysfunction, or early 
decompensation, since they presented with higher fasting glucose but no real reduction in β-cell 
mass or density. Stage 3 has been reported to be extremely unstable and may be the critical step 
leading to T2DM (106). Some patients remain in this stage for excessive periods of time and 
continue having moderate blood glucose impairment while others progress rapidly into the fourth 
stage, marked by significant decreases in β-cell mass (106). Mice exposed to chronic E-cig vapor 
presented with significantly higher resting and stimulated blood glucose following 4 hours of 
exposure indicating either a reduced ability to secrete appropriate insulin levels or a reduced 
ability to respond to secreted insulin by peripheral tissues.  
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 Body weights were not different between E-cig and control mice throughout the study. 
Adipose tissue collected and weighed at the time of sacrifice were also not different between 
groups (data not shown). Because of this, we assumed that any differences in blood glucose did 
not arise from excessive adiposity or the associated pathologies from being overweight, but from 
the exposure itself. Nicotine is a known appetite inhibitor, whereas some sweeteners used in the 
e-liquid flavorings are known to increase appetite (109). El Golli et al tested the effects of E-
liquid both with and without nicotine, and found increased glycemia in both groups (90). This 
supports our finding that the blood glucose is increased regardless of blood nicotine following 
exposure. More research is needed on this interaction (both in terms of nicotine and E-liquid, and 
E-liquid alone) to further understand the mechanisms at play and provide some insight into the 
differences seen in glucose metabolism without the weight gain typically associated with a 
T2DM phenotype. More research is needed in peripheral tissues (i.e. liver and skeletal muscle) to 
further characterize the potential effects that E-cig exposure may have on glucose handling. 
 SIRT1 has been shown to help regulate blood glucose by its ability to enhance glucose 
stimulated insulin release from the β-cells (49). It may do this in part, through its ability to 
downregulate UCP2. It has been postulated that SIRT1 decreases UCP2 levels in the β-cells by 
binding directly to the UCP2 promoter in order to silence it (23). Therefore, when SIRT1 is 
present in acceptable levels it allows energy coupling to proceed as normal. Reduction in UCP2 
has been shown to restore normal insulin secretion (23). Results from the present study 
demonstrated that the total SIRT1 protein level of the pancreas was not different between groups 
while the density of SIRT1 positive β-cells where reduced following chronic E-cig exposure. 
Histochemical analysis of pancreatic sections revealed SIRT1 positive β-cells in the islets 
examined. Quantifying these images relied on some measure of subjectivity, which was partially 
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mitigated by having only one person examine and count the images. Representative pictures are 
included (Figure 7C) indicating what was counted as a SIRT1(+) nucleus. The E-cig pancreas 
presented with less SIRT1(+) nuclei per islet area compared with controls. The significance here 
is likely due to the trending differences in both mean SIRT1(+) nuclei and islet area, with some 
of the variance accounted for by both measures, allowing SIRT1(+) density to reach significance. 
Reduced pancreatic SIRT1 has been shown to result in impairments in insulin secretion (23, 50) 
and increased UCP2 (23), which is what we saw to some degree. We found that UCP2 protein 
tended to decrease, although not significantly, in the E-cig mice. This could be due to running 
the analysis on whole pancreas tissue. We saw the differences in SIRT1 specifically within the 
islets of the pancreas, so this limits our ability to relate these two findings and could explain the 
lack of significance for the SIRT1 ELISA. Although the protein levels appeared to be slightly 
higher, the SIRT1(+) β-cell density was lower in E-cig mice when normalized to islet area. 
Again, the limited sample size analyzed is likely an important factor. Examining the protein 
levels in a greater number of animals may help better define the SIRT1 response to chronic E-cig 
exposure. If we had isolated islets in the beginning, we may have also seen significant 
differences in SIRT1. 
 Oxidative stress has been shown to blunt SIRT1’s activity in the pancreas (107). The 
animals exposed to E-cig vapor were undergoing near constant oxidative stress to their lungs and 
other organ systems (110), which could have contributed to the overall dysfunction of the 
pancreas without overt histological pathologies or differences (91). The fact that we saw a slight 
increase in total pancreas SIRT1 but decreased islet SIRT1 could strengthen the argument that 
these exposed animals are in an early state of decompensation, where the decompensatory 
mechanism acts first in the β-cells assuming the mechanism for SIRT1 dysfunction is similar to 
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that of the whole pancreas (an initial hypertrophy accompanied by adequate compensation 
followed by atrophy and decompensation). 
Limitations	  and	  Future	  Directives	  
 The most notable limitation in the study is the lack of breadth in terms of blood 
nicotine/blood glucose data. The glucose tolerance tests allow only a brief glimpse into what is 
actually occurring metabolically with these animals and the study would have greatly benefitted 
from regular glucose testing, beginning much earlier in the study and continuing at a regular 
interval until the conclusion of the exposures. With this data, it would be easier to interpret the 
effect that the E-cig had on glucose handling. Second, it would have been prudent to periodically 
measure blood insulin and the insulin response throughout the study. There was an attempt at an 
IP insulin tolerance test, but due to unforeseen circumstances the mice became excessively 
hypoglycemic and the test had to be aborted for the well being of the mice. Even though no 
usable data came of the test, the E-cig animals appeared less hypoglycemic than the others. 
Finally, regular, or at least semi-regular, testing of blood nicotine post smoke exposure would 
also be beneficial. Cotinine, a stable metabolite of nicotine, levels were assessed via urine 
samples but do not provide the same picture of the nicotine profile the animals were 
experiencing. Future studies should incorporate regular and more frequent testing of blood 
glucose, insulin, and nicotine, perhaps at the end of every week.  
 Another potential limitation is that when pancreas samples were taken, there was only 
one small section cut away from the entire tissue to be preserved for histology. During tissue 
cutting on the cryostat, there were serial cuts of the same area of tissue. Literature exists 
supporting the notion that different regions of the pancreas (i.e. ventral vs. dorsal regsions) have 
different densities of β-cells (111, 112, 113). When portions were taken in our study, their 
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locations were not recorded as adequate tissue had to be preserved for protein analysis. Taking 
more samples from different loci within the tissue might prove insightful, as different islets can 
be better isolated that way. This might be a more robust way to tease out differences in islet area 
and β-cell density.  
 Additionally, there was one animal within the chosen subset that brought down all 
averages for β-cell number, density, and islet area. When this one animal is removed, β-cell 
density and islet area become statistically significant, with density significantly decreased and 
area significantly increased. There is no reason to exclude this animal, but this speaks for the 
conclusion that an increased sample size would have accounted for this and allowed the averages 
to reach significance.  
 In order to more fully understand the full effect nicotine has on the pancreas, further 
research is needed that involves varying concentrations of nicotine. For our study, we used 
18mg/mL, but E-liquid can be made with almost any nicotine concentration ranging from 0-
>50mg/mL. A study that looks at 0 mg/mL nicotine vs low nicotine content (5-10mg/mL) high 
nicotine content (18+mg/mL) may prove more effective in understanding the role nicotine plays 
on the destruction of proper function in the pancreas. Looking at E-liquid with 0 mg/mL nicotine 
would allow a better look at what these flavorings specifically are doing to the body and how 
they may or may not be altering overall glucose metabolism.  
 In future studies, assessment of α-cell morphology and glucagon protein content may also 
be of some benefit. Since there was significant glucose impairment but no apparent changes to β-
cell morphology, it stands to reason that α-cells may also play a role in the development of this 
impairment (85). One might expect to see hypertrophied α-cells, as a direct result of constant 
stimulation from catecholamines in response to the nicotine dosage. This could possibly explain 
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the changes in glucose metabolism despite not seeing significant differences in β-cell 
morphology.  
 A more in depth look at pancreas and muscle proteins may also help to tease out specific 
differences in content. There may also be some merit to examining muscle morphology for 
GLUT4 translocation to determine effectiveness of glucose uptake at the level of the skeletal 
muscle. Because SIRT1 regulates transcription of FoxO1, which is responsible for Akt 
phosphorylation, SIRT1 and GLUT4 are tightly related. Much more information is required to 
fully understand how SIRT1 works, not just in β-cells but as a whole body mechanism. Possible 
future studies could look into performing smoke/vapor exposures with SIRT1 knockouts and 
SIRT1 global overexpressers to see if they respond in the same hyperglycemic manner as both 
each other and control. 
 In conclusion, we found that chronic exposure to E-cig vapor significantly alters glucose 
metabolism in that fasting blood glucose and glucose response are both increased after an acute 
E-cig exposure. These animals are believed to be in a state of pancreatic decompensation due to 
lack of morphological differences but presence of hyperglycemia. We also showed that 
SIRT1(+) β-cells decreased within the pancreatic islets. More differences may be teased out with 
a greater sample size.  
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FIGURE LEGENDS 
	  
Figure	  1A. Mouse body weights in (g) over the 8 month exposure. N=13 for each group. All 
data are represented as a mean ± SE. 
	  
Figure	  1B. Mouse body weights in (g) at 6 months of exposure. N=13 for each group. All data 
are represented as a mean ± SE. 
 
Figure	  1C. Mouse body weights in (g) at 8 months of exposure. N=13 for each group. All data 
are represented as a mean ± SE. 
 
Figure	  2A. Fasting blood glucose measurements taken on a weekend (48 hours post exposure). 
Animals were fasted 8 hours. N=6 for each group. All data represented as a mean ± SE. 
 
Figure	  2B. Fasting blood glucose measurements taken after a typical 4-hour exposure period. 
Animals were fasted 8 hours. N=6 for each group. All data represented as a mean ± SE. 
 
Figure	  2C. An oral glucose tolerance test was administered at 2g glucose/kg body mass after 8-
hour fast (48-hours post exposure). N=6 for each group. All data represented as a mean ± SE. 
 
Figure	  2D. An oral glucose tolerance test was administered at 2g glucose/kg body mass after 8-
hour fast and a typical 4-hour exposure period. N=6 for each group. All data represented as a 
mean ± SE. 
 
Figure	  3. Blood glucose measurements taken post 8-hour fast and a typical 4-hour exposure 
period at the 6-month exposure time point during IPGTT. N=4 for each group. All data are 
represented as a mean ± SE. P=0.05 
 
Figure	  4A. Intraperitoneal glucose tolerance test where glucose bolus was given at 2g 
glucose/kg body mass after 8-hour fast and 4-hour smoking exposure. N=4 for each group. All 
data are represented as a mean ± SE.  
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Figure	  4A. IPGTT curve with E-cig curve accounted for increased baseline measurements. N=4 
for each group. All data are represented as a mean ± SE. P=0.05. 
 
Figure	  4C. Peak blood glucose, corresponding to the highest blood glucose reading reached 
during the test, occurring at 15min. N=4 for each group. All data represented as a mean ± SE. 
P<0.04. 
 
Figure	  4D. Area under the glucose tolerance curve in arbitrary units squared. N=4 for each 
group. All data are represented as a mean ± SE. P<0.02. 
 
Figure	  5A. Average β-cell number within insulin positive area. N=6 for each group. All data are 
represented as a mean ± SE. 
 
Figure	  5B. Average β-cell density [number of β-cells /islet (insulin positive area)]. N=6 for each 
group. All data are represented as a mean ± SE.  
 
Figure	  6A. Average islet (insulin positive) area. N=6 for each group. All data are represented as 
a mean ± SE.  
 
Figure	  6B. Representative image showing DAPI (blue) and insulin (red) stains. 
 
Figure	  7A. Representative image showing how SIRT(+) nuclei were determined and counted 
(green nuclei within red insulin positive area). 
 
Figure	  7B. Average SIRT(+) nuclei contained in a single islet. N=6 for each group.  All data are 
represented as a mean ± SE.  
 
Figure	  7C. Average SIRT(+) density, number of SIRT(+) nuclei per islet area. N=6 for each 
group.  All data are represented as a mean ± SE. P=0.05. 
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Figure	  8. SIRT1 protein concentration in whole pancreas tissue homogenate as determined by 
ELISA kit (Abcam). N=5 for E-cig, N=9 for control. All data are represented as a mean ± SE. 
 
Figure	  9. UCP2 protein concentration in whole pancreas tissue homogenate. N=8 for each 
group. All data are represented as a mean ± SE.  
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FIGURES 
	   Figure	  1A.	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